University Deal Valuations
How do the financial terms of deals signed with university tech transfer offices differ when the licensor is a biotech, compared to a Big Pharma? We broke out university deals signed by these kinds of licensors to find out.
You may also be interested in...
In Vivo reviews recent royalty rates in tech transfer-to-biotech licensing deals.
The EU’s Medical Device Regulation applies in just over a month’s time and the IVD Regulation in just over a year. But the standards underpinning them are way behind. Will they get the green light at last
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.